Takamatsu, Shiro http://orcid.org/0000-0002-1569-6421
Hillman, R. Tyler
Yoshihara, Kosuke http://orcid.org/0000-0002-2254-3378
Baba, Tsukasa
Shimada, Muneaki
Yoshida, Hiroshi
Kajiyama, Hiroaki
Oda, Katsutoshi http://orcid.org/0000-0002-2468-9573
Mandai, Masaki
Okamoto, Aikou
Enomoto, Takayuki
Matsumura, Noriomi http://orcid.org/0000-0002-4512-7975
Funding for this research was provided by:
AstraZeneca K.K. and Merck Sharp & Dohme Corp as the programme of Externally Sponsored Research
Japan Agency for Medical Research and Development (JP21tm0124005)
Article History
Received: 24 April 2024
Revised: 20 August 2024
Accepted: 23 August 2024
First Online: 30 August 2024
Competing interests
: NM received a research grant from AstraZeneca. NM received lecture fees from AstraZeneca, Takeda Pharmaceutical, Eisai, MSD and Chugai Pharmaceutical, and is an outside director of Takara Bio. TB received lecture fees from AstraZeneca. KY received lecture fees and a research grant from AstraZeneca. There are no other competing interests related to this paper.
: For the JGOG3025 study, i.e., clinical data analysis, frozen tumor tissue collection, target sequencing, and future analyses of tumor tissue, written informed consent was obtained from all patients with approval from the Institutional Review Board at each JGOG participating site prior to the start of the study []. The JGOG3025-TR2 study was then conducted with the approval of the Ethics Committee of JGOG and the Institutional Ethics Committee of Kindai University (approval number; 29-167), with opt-out patient consent. This study was performed in accordance with the Declaration of Helsinki.